Theravance Biopharma, Inc. $148.5 Million Follow-On Offering

Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares are listed on the Nasdaq Global Market under the symbol “TBPH.”

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines.

The Davis Polk corporate team included partner Alan F. Denenberg and associate Dongbiao Shen. Partner Mario J. Verdolini and associate Adam R. Brownstone provided tax advice. Partner David R. Bauer and associate Gianna C. Walton provided intellectual property advice. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.